Richard Sullivan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5475378/publications.pdf

Version: 2024-02-01

282 papers

17,928 citations

51 h-index 123 g-index

287 all docs

287 docs citations

times ranked

287

24047 citing authors

#	Article	IF	CITATIONS
1	Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development. Lancet, The, 2015, 386, 569-624.	6.3	2,466
2	The burden of disease in older people and implications for health policy and practice. Lancet, The, 2015, 385, 549-562.	6.3	1,393
3	The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncology, The, 2020, 21, 1023-1034.	5.1	1,236
4	Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncology, The, 2013, 14, 1165-1174.	5.1	718
5	The global burden of women's cancers: a grand challenge in global health. Lancet, The, 2017, 389, 847-860.	6.3	666
6	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 2015, 26, 1547-1573.	0.6	635
7	Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ, The, 2020, 371, m4087.	3.0	606
8	Delivering affordable cancer care in high-income countries. Lancet Oncology, The, 2011, 12, 933-980.	5.1	571
9	Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncology, The, 2015, 16, 1193-1224.	5.1	442
10	Challenges to effective cancer control in China, India, and Russia. Lancet Oncology, The, 2014, 15, 489-538.	5.1	411
11	Planning cancer control in Latin America and the Caribbean. Lancet Oncology, The, 2013, 14, 391-436.	5.1	394
12	The growing burden of cancer in India: epidemiology and social context. Lancet Oncology, The, 2014, 15, e205-e212.	5.1	290
13	Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open, 2020, 10, e043828.	0.8	233
14	Economic Burden of Bladder Cancer Across the European Union. European Urology, 2016, 69, 438-447.	0.9	223
15	Medicinal Mushrooms and Cancer Therapy: translating a traditional practice into Western medicine. Perspectives in Biology and Medicine, 2006, 49, 159-170.	0.3	214
16	Title is missing!. Biotechnology Letters, 2002, 24, 1839-1845.	1.1	181
17	Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncology, The, 2020, 21, e185-e224.	5.1	177
18	Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development. International Journal of Obstetric Anesthesia, 2016, 25, 75-78.	0.2	175

#	Article	IF	CITATIONS
19	Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study. Lancet Oncology, The, 2021, 22, 1507-1517.	5.1	171
20	Delivery of affordable and equitable cancer care in India. Lancet Oncology, The, 2014, 15, e223-e233.	5.1	169
21	The State of Lung Cancer Research: A Global Analysis. Journal of Thoracic Oncology, 2016, 11, 1040-1050.	0.5	166
22	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	5.1	153
23	The Lancet Commission on diagnostics: transforming access to diagnostics. Lancet, The, 2021, 398, 1997-2050.	6.3	149
24	Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: a longitudinal analysis. Lancet, The, 2016, 388, 684-695.	6.3	137
25	ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Annals of Oncology, 2016, 27, 1423-1443.	0.6	137
26	Global Surgery 2030: Evidence and solutions for achieving health, welfare, and economic development. Surgery, 2015, 158, 3-6.	1.0	126
27	Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncology, The, 2014, 15, e119-e131.	5.1	124
28	Global Surgery 2030: a roadmap for high income country actors. BMJ Global Health, 2016, 1, e000011.	2.0	114
29	The COVIDâ€19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOPâ€E, SIOPâ€PODC, IPSO, PROS, CCI, and St Jude Global. Pediatric Blood and Cancer, 2020, 67, e28409.	0.8	113
30	Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncology, The, 2017, 18, 887-894.	5.1	108
31	Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund. Annals of Oncology, 2017, 28, 1738-1750.	0.6	102
32	Priorities for cancer research in low- and middle-income countries: a global perspective. Nature Medicine, 2022, 28, 649-657.	15,2	101
33	Trends in the global funding and activity of cancer research. Molecular Oncology, 2008, 2, 20-32.	2.1	96
34	New policies to address the global burden of childhood cancers. Lancet Oncology, The, 2013, 14, e125-e135.	5.1	96
35	Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncology, The, 2022, 23, e251-e312.	5.1	94
36	Cancer Control in Bangladesh. Japanese Journal of Clinical Oncology, 2013, 43, 1159-1169.	0.6	91

#	Article	IF	CITATIONS
37	ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe. Annals of Oncology, 2017, 28, 2633-2647.	0.6	87
38	Delivering modern, high-quality, affordable pathology and laboratory medicine to low-income and middle-income countries: a call to action. Lancet, The, 2018, 391, 1953-1964.	6.3	83
39	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
40	A narrative review of health research capacity strengthening in low and middle-income countries: lessons for conflict-affected areas. Globalization and Health, 2019, 15, 23.	2.4	81
41	An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncology, 2021, 7, 379.	3.4	81
42	Eradicating polio in Pakistan: an analysis of the challenges and solutions to this security and health issue. Globalization and Health, 2016, 12, 63.	2.4	74
43	Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study. Lancet Oncology, The, 2017, 18, 1445-1453.	5.1	74
44	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncology, The, 2021, 22, 1367-1377.	5.1	69
45	Changing global policy to deliver safe, equitable, and affordable care for women's cancers. Lancet, The, 2017, 389, 871-880.	6.3	66
46	Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?. Annals of Oncology, 2017, 28, 157-162.	0.6	66
47	Cancer research in India: national priorities, global results. Lancet Oncology, The, 2014, 15, e213-e222.	5.1	62
48	How do the media report cancer research? A study of the UK's BBC website. British Journal of Cancer, 2008, 99, 569-576.	2.9	61
49	Rho Controls Cortical F-actin Disassembly in Addition to, but Independently of, Secretion in Mast Cells. Journal of Biological Chemistry, 1999, 274, 38140-38146.	1.6	58
50	The SIOPE strategic plan: A European cancer plan for children and adolescents. Journal of Cancer Policy, 2016, 8, 17-32.	0.6	57
51	Cancer Care for Refugees and Displaced Populations: Middle East Conflicts and Global Natural Disasters. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 433-440.	1.8	57
52	Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states. Annals of Oncology, 2013, 24, 2897-2902.	0.6	56
53	Patient Mobility for Elective Secondary Health Care Services in Response to Patient Choice Policies: A Systematic Review. Medical Care Research and Review, 2017, 74, 379-403.	1.0	55
54	The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. The Lancet Gastroenterology and Hepatology, 2021, 6, 709-722.	3.7	52

#	Article	IF	CITATIONS
55	Radiation Therapy Research: A Global Analysis 2001-2015. International Journal of Radiation Oncology Biology Physics, 2018, 101, 767-778.	0.4	51
56	Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London. Frontiers in Oncology, 2020, 10, 1279.	1.3	49
57	Financial Toxicity After Cancer in a Setting With Universal Health Coverage: A Call for Urgent Action. Journal of Oncology Practice, 2019, 15, e537-e546.	2.5	48
58	Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK. European Journal of Cancer, 2021, 152, 233-242.	1.3	48
59	Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care. Lancet Oncology, The, 2019, 20, e218-e223.	5.1	47
60	Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study. Lancet Oncology, The, 2021, 22, 182-189.	5.1	47
61	Cancer patients need better care, not just more technology. Nature, 2017, 549, 325-328.	13.7	46
62	Calmodulin regulates the disassembly of cortical F-actin in mast cells but is not required for secretion. Cell Calcium, 2000, 28, 33-46.	1,1	43
63	Creating a low-cost virtual reality surgical simulation to increase surgical oncology capacity and capability. Ecancermedicalscience, 2019, 13, 910.	0.6	43
64	The impact of cancer research: how publications influence UK cancer clinical guidelines. British Journal of Cancer, 2008, 98, 1944-1950.	2.9	41
65	Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. British Journal of Cancer, 2021, 125, 939-947.	2.9	41
66	Economics of Cancer Medicines: For Whose Benefit?. New Bioethics, 2017, 23, 95-104.	0.5	39
67	Cancer and coronavirus disease 2019; how do we manage cancer optimally through a public health crisis?. European Journal of Cancer, 2020, 132, 98-99.	1.3	39
68	Health technology assessment in universal health coverage. Lancet, The, 2013, 382, e48-e49.	6.3	38
69	An assessment of the barriers to accessing the Basic Package of Health Services (BPHS) in Afghanistan: was the BPHS a success?. Globalization and Health, 2016, 12, 71.	2.4	38
70	Disinformation and Epidemics: Anticipating the Next Phase of Biowarfare. Health Security, 2021, 19, 3-12.	0.9	38
71	Documenting attacks on health workers and facilities in armed conflicts. Bulletin of the World Health Organization, 2017, 95, 79-81.	1.5	38
72	Affordable cancer care: pipedream or achievable reality?. Lancet Oncology, The, 2014, 15, 257-258.	5.1	36

#	Article	IF	CITATIONS
73	The European Cancer Patient's Bill of Rights, update and implementation 2016. ESMO Open, 2016, 1, e000127.	2.0	36
74	Addressing COVID-19 in humanitarian settings: a call to action. Conflict and Health, 2020, 14, 64.	1.0	36
75	A Survey of Public Funding of Cancer Research in the European Union. PLoS Medicine, 2006, 3, e267.	3.9	35
76	Children with cancer: driving the global agenda. Lancet Oncology, The, 2013, 14, 189-191.	5.1	35
77	A Catalyst for Change: The European Cancer Patient's Bill of Rights. Oncologist, 2014, 19, 217-224.	1.9	35
78	Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: national cohort study in England. British Journal of Cancer, 2016, 115, 1408-1415.	2.9	35
79	Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients. Thorax, 2018, 73, 530-537.	2.7	35
80	Mapping the European cancer research landscape: An evidence base for national and Pan-European research and funding. European Journal of Cancer, 2018, 100, 75-84.	1.3	34
81	Cancer care workforce in Africa: perspectives from a global survey. Infectious Agents and Cancer, 2019, 14, 11.	1.2	34
82	Estimating indirect mortality impacts of armed conflict in civilian populations: panel regression analyses of 193 countries, 1990–2017. BMC Medicine, 2020, 18, 266.	2.3	34
83	"Nudge―in the clinical consultation – an acceptable form of medical paternalism?. BMC Medical Ethics, 2014, 15, 31.	1.0	33
84	Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition. European Urology, 2018, 73, 822-825.	0.9	33
85	Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres. Lancet Oncology, The, 2018, 19, e395-e406.	5.1	33
86	Delivery of Global Cancer Care: An International Study of Medical Oncology Workload. Journal of Global Oncology, 2018, , 1-11.	0.5	32
87	Understanding the impact of public policy on cancer research: A bibliometric approach. European Journal of Cancer, 2010, 46, 912-919.	1.3	31
88	The economic burden of cancer care for Syrian refugees: a population-based modelling study. Lancet Oncology, The, 2020, 21, 637-644.	5.1	30
89	The impact of national non-pharmaceutical interventions (†lockdowns') on the presentation of cancer patients. Ecancermedicalscience, 2021, 15, 1180.	0.6	30
90	Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. Seminars in Cancer Biology, 2022, 84, 293-301.	4.3	30

#	Article	IF	CITATIONS
91	The effect of explosive remnants of war on global public health: a systematic mixed-studies review using narrative synthesis. Lancet Public Health, The, 2017, 2, e286-e296.	4.7	29
92	The identity and Work of the Ancient Egyptian Surgeon. Journal of the Royal Society of Medicine, 1996, 89, 467-473.	1.1	28
93	The State of Research and Development in Global Cancer Surgery. Annals of Surgery, 2012, 255, 427-432.	2.1	28
94	Affordability of cancer care in the United Kingdom – Is it time to introduce user charges?. Journal of Cancer Policy, 2014, 2, 31-39.	0.6	28
95	High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of re-admission and death: National cohort analysis in England. European Journal of Cancer, 2016, 64, 32-43.	1.3	28
96	Hospital Quality Factors Influencing the Mobility of Patients for Radical Prostate Cancer Radiation Therapy: A National Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1261-1270.	0.4	28
97	The Profile of Non-Communicable Disease (NCD) research in the Middle East and North Africa (MENA) region: Analyzing the NCD burden, research outputs and international research collaboration. PLoS ONE, 2020, 15, e0232077.	1.1	28
98	Cancer and mental health—a clinical and research unmet need. Annals of Oncology, 2013, 24, 2274-2278.	0.6	27
99	Primary care and cancer: an analysis of the impact and inequalities of the COVID-19 pandemic on patient pathways. BMJ Open, 2022, 12, e059374.	0.8	27
100	A snapshot of cancer in Chile: analytical frameworks for developing a cancer policy. Biological Research, 2015, 48, 10.	1.5	26
101	Lockdown is not egalitarian: the costs fall on the global poor. Lancet, The, 2020, 396, 21-22.	6.3	26
102	Dispelling the myths around cancer care delivery: It's not all about costs. Journal of Cancer Policy, 2014, 2, 22-29.	0.6	25
103	The challenge of cancer in middle-income countries with an ageing population: Mexico as a case study. Ecancermedicalscience, 2015, 9, 536.	0.6	25
104	Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development. American Journal of Obstetrics and Gynecology, 2015, 213, 338-340.	0.7	25
105	Economic burden of malignant blood disorders across Europe: a population-based cost analysis. Lancet Haematology,the, 2016, 3, e362-e370.	2.2	25
106	The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. Lancet Oncology, The, 2021, 22, e369-e376.	5.1	25
107	Cancer groundshot: going global before going to the moon. Lancet Oncology, The, 2018, 19, 288-290.	5.1	24
108	The role of public health information in assistance to populations living in opposition and contested areas of Syria, 2012–2014. Conflict and Health, 2017, 11, 33.	1.0	23

#	Article	IF	CITATIONS
109	Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. European Journal of Cancer, 2018, 104, 127-136.	1.3	23
110	Cancer in Africa: the way forward. Ecancermedicalscience, 2019, 13, 953.	0.6	23
111	Online information as a decision making aid for cancer patients: Recommendations from the Eurocancercoms project. European Journal of Cancer, 2012, 48, 1055-1059.	1.3	22
112	The European Code of Cancer Practice. Journal of Cancer Policy, 2021, 28, 100282.	0.6	22
113	North–South inequities in research collaboration in humanitarian and conflict contexts. Lancet, The, 2019, 394, 1597-1600.	6.3	21
114	The role of funding and policies on innovation in cancer drug development. Ecancermedicalscience, 2010, 4, 164.	0.6	20
115	Critical Appraisal of Translational Research Models for Suitability in Performance Assessment of Cancer Centers. Oncologist, 2012, 17, e48-e57.	1.9	20
116	Health system strengthening: Integration of breast cancer care for improved outcomes. Cancer, 2020, 126, 2353-2364.	2.0	20
117	Cancer and COVID-19 vaccines: a complex global picture. Lancet Oncology, The, 2021, 22, 749-751.	5.1	20
118	Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study. European Journal of Cancer, 2021, 155, 136-144.	1.3	20
119	The impact of armed conflict on cancer among civilian populations in low- and middle-income countries: a systematic review. Ecancermedicalscience, 2020, 14, 1039.	0.6	20
120	Why do we love medicines so much?. EMBO Reports, 2010, 11, 572-578.	2.0	19
121	Lessons learned from the casualties of war: battlefield medicine and its implication for global trauma care. Journal of the Royal Society of Medicine, 2015, 108, 93-100.	1.1	19
122	European Non-Communicable Respiratory Disease Research, 2002-13: Bibliometric Study of Outputs and Funding. PLoS ONE, 2016, 11, e0154197.	1.1	19
123	ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers. ESMO Open, 2016, 1, e000100.	2.0	18
124	Nutritional Online Information for Cancer Patients: a Randomized Trial of an Internet Communication Plus Social Media Intervention. Journal of Cancer Education, 2016, 31, 472-480.	0.6	18
125	Intelligence and global health: assessing the role of open source and social media intelligence analysis in infectious disease outbreaks. Zeitschrift Fur Gesundheitswissenschaften, 2018, 26, 509-514.	0.8	18
126	Using Low-Cost Virtual Reality Simulation to Build Surgical Capacity for Cervical Cancer Treatment. Journal of Global Oncology, 2019, 5, 1-7.	0.5	18

#	Article	IF	CITATIONS
127	Cancer Registration in the Middle East, North Africa, and Turkey: Scope and Challenges. JCO Global Oncology, 2021, 7, 1101-1109.	0.8	18
128	Statistical analyses in Swedish randomised trials on mammography screening and in other randomised trials on cancer screening: a systematic review. Journal of the Royal Society of Medicine, 2015, 108, 440-450.	1.1	17
129	"Nudge―and the epidemic of missed appointments. Journal of Health Organization and Management, 2016, 30, 558-564.	0.6	17
130	Cancer in Europe: Death sentence or life sentence?. European Journal of Cancer, 2016, 65, 150-155.	1.3	17
131	Weaponizing water as an instrument of war in Syria: Impact on diarrhoeal disease in Idlib and Aleppo governorates, 2011–2019. International Journal of Infectious Diseases, 2021, 108, 202-208.	1.5	17
132	Cancer and COVID-19: economic impact on households in Southeast Asia. Ecancermedicalscience, 2020, 14, 1134.	0.6	17
133	COVID-19 and the Rise of Participatory SIGINT: An Examination of the Rise in Government Surveillance Through Mobile Applications. American Journal of Public Health, 2020, 110, 1780-1785.	1.5	16
134	COVID-19, palliative careÂand public health. European Journal of Cancer, 2020, 136, 95-98.	1.3	16
135	COVID-19â€"Impact on DNR Orders in the Largest Cancer Center in Jordan. Journal of Pain and Symptom Management, 2020, 60, e87-e89.	0.6	16
136	Medical oncology in India: Workload, infrastructure, and delivery of care. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 121-127.	0.1	16
137	Prioritising locations for radiotherapy equipment in Brazil: a cross-sectional, population-based study and development of a LINAC shortage index. Lancet Oncology, The, 2022, 23, 531-539.	5.1	16
138	Conflicts of interest statements on biomedical papers. Scientometrics, 2015, 102, 2151-2159.	1.6	15
139	Putting a price on cancer. Nature Reviews Clinical Oncology, 2016, 13, 137-138.	12.5	15
140	Medical oncology job satisfaction: Results of a global survey. Seminars in Oncology, 2019, 46, 73-82.	0.8	15
141	Medical Oncology Workload in Europe: One Continent, Several Worlds. Clinical Oncology, 2020, 32, e19-e26.	0.6	15
142	"Having more women humanitarian leaders will help transform the humanitarian system― challenges and opportunities for women leaders in conflict and humanitarian health. Conflict and Health, 2020, 14, 84.	1.0	15
143	Darwin, medicine and cancer. Annals of Oncology, 2010, 21, 199-203.	0.6	14
144	European diabetes research and its funding, 2002–2013. Diabetic Medicine, 2017, 34, 1354-1360.	1.2	14

#	Article	IF	CITATIONS
145	Medical Oncology Workload in Canada: Infrastructure, Supports, and Delivery of Clinical Care. Current Oncology, 2018, 25, 206-212.	0.9	14
146	India's new health scheme: what does it mean for cancer care?. Lancet Oncology, The, 2019, 20, 757-758.	5.1	14
147	Global public and philanthropic investment in childhood cancer research: systematic analysis of research funding, 2008–16. Lancet Oncology, The, 2019, 20, e672-e684.	5.1	14
148	User Experience With Low-Cost Virtual Reality Cancer Surgery Simulation in an African Setting. JCO Global Oncology, 2021, 7, 435-442.	0.8	14
149	Is Clinical Research Serving the Needs of the Global Cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials. International Journal of Radiation Oncology Biology Physics, 2022, 113, 500-508.	0.4	14
150	Perioperative therapies – Enhancing the impact of cancer surgery with repurposed drugs. European Journal of Surgical Oncology, 2017, 43, 1985-1988.	0.5	13
151	A roadmap for restoring trust in Big Data. Lancet Oncology, The, 2018, 19, 1014-1015.	5.1	13
152	Cancer control in small island nations: from local challenges to global action. Lancet Oncology, The, 2019, 20, e535-e548.	5.1	13
153	Late translational research: putting forward a new model for developing new antiâ ϵ ancer treatments that addresses the needs of patients and society. Molecular Oncology, 2019, 13, 558-566.	2.1	13
154	Analysis of Global Pediatric Cancer Research and Publications. JCO Global Oncology, 2020, 6, 9-18.	0.8	13
155	COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients. Cancers, 2021, 13, 2479.	1.7	13
156	Cancer care in times of conflict: cross border care in Pakistan of patients from Afghanistan. Ecancermedicalscience, 2020, 14, 1018.	0.6	13
157	Contributions to Senescence: Non-Enzymatic Glycosylation of Proteins. Archives of Physiology and Biochemistry, 1996, 104, 797-806.	1.0	12
158	Avoiding the zero sum game in global cancer policy: Beyond 2011 UN high level summit. European Journal of Cancer, 2011, 47, 2375-2380.	1.3	12
159	Financial Impact of Complex Cancer Surgery in India: A Study of Pancreatic Cancer. Journal of Global Oncology, 2018, 4, 1-9.	0.5	12
160	Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses. Oncotarget, 2019, 10, 3408-3423.	0.8	12
161	A prospective study to determine the cost of illness for oral cancer in India. Ecancermedicalscience, 2021, 15, 1252.	0.6	12
162	Global cancer research in the era of COVID-19: a bibliometric analysis. Ecancermedicalscience, 2021, 15, 1264.	0.6	12

#	Article	IF	Citations
163	Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians. Nature Medicine, 2021, 27, 1324-1327.	15.2	12
164	Divine and Rational. Obstetrical and Gynecological Survey, 1997, 52, 635-642.	0.2	12
165	Cancer among syrian refugees living in Konya Province, Turkey. Conflict and Health, 2022, 16, 3.	1.0	12
166	The good, the bad, and the ugly: effect of regulations on cancer research. Lancet Oncology, The, 2008, 9, 2-3.	5.1	11
167	Personalised and Precision Medicine in Cancer Clinical Trials: Panacea for Progress or Pandora's Box?. Public Health Genomics, 2015, 18, 329-337.	0.6	11
168	Impact of patient choice and hospital competition on patient outcomes after prostate cancer surgery: A national populationâ€based study. Cancer, 2019, 125, 1898-1907.	2.0	11
169	Silver linings: a qualitative study of desirable changes to cancer care during the COVID-19 pandemic. Ecancermedicalscience, 2021, 15, 1202.	0.6	11
170	Proto-Surgery in Ancient Egypt. Acta Medica (Hradec Kralove), 1998, 41, 109-120.	0.2	11
171	Global cancer research in the post-pandemic world. Lancet Oncology, The, 2021, 22, 1652-1654.	5.1	11
172	European Clinical Trials Directive: responses made to MHRA consultation letter MLX 287. Lancet, The, 2003, 362, 1415.	6.3	10
173	The state of academic cancer surgery in the UK. Molecular Oncology, 2008, 2, 206-212.	2.1	10
174	An analysis of research activity in major UK cancer centres. European Journal of Cancer, 2011, 47, 536-544.	1.3	10
175	Lung cancer researchers, 2008–2013: their sex and ethnicity. Scientometrics, 2016, 106, 105-117.	1.6	10
176	Palliative Care Program Development in a Low- to Middle-Income Country: Delivery of Care by a Nongovernmental Organization in India. Journal of Global Oncology, 2018, 4, 1-8.	0.5	10
177	Alignment with Indices of A Care Pathway Is Associated with Improved Survival. EClinicalMedicine, 2019, 15, 42-50.	3.2	10
178	Solving the jigsaw of conflict-related environmental damage: Utilizing open-source analysis to improve research into environmental health risks. Journal of Public Health, 2020, 42, e352-e360.	1.0	10
179	A Health Intelligence Framework for Pandemic Response: Lessons from the UK Experience of COVID-19. Health Security, 2020, 18, 435-443.	0.9	10
180	Compounded trauma: A qualitative study of the challenges for refugees living with advanced cancer. Palliative Medicine, 2021, 35, 916-926.	1.3	10

#	Article	IF	Citations
181	The UK's contribution to cancer control in low-income and middle-income countries. Lancet Oncology, The, 2021, 22, e410-e418.	5.1	10
182	Ecology of War, Health Research and Knowledge Subjugation: Insights from the Middle East and North Africa Region. Annals of Global Health, 2020, 86, 120.	0.8	10
183	Public knowledge and attitudes concerning palliative care. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2021-003340.	0.8	10
184	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 423.	0.6	9
185	The hazards of reproduction in space. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 372-377.	1.3	9
186	Missionâ€oriented translational cancer research – health economics. Molecular Oncology, 2019, 13, 636-647.	2.1	9
187	Costâ€effectiveness of precision diagnostic testing for precision medicine approaches against nonâ€smallâ€eell lung cancer: A systematic review. Molecular Oncology, 2021, 15, 2672-2687.	2.1	9
188	Observed and Predicted Risk of Breast Cancer Death in Randomized Trials on Breast Cancer Screening. PLoS ONE, 2016, 11, e0154113.	1.1	9
189	Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England. Journal of Cancer Policy, 2022, 31, 100316.	0.6	9
190	Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence. Journal of Cancer Policy, 2022, 33, 100340.	0.6	9
191	Has the US Cancer Centre model been †successful'? Lessons for the European cancer community. Molecular Oncology, 2009, 3, 192-203.	2.1	8
192	How are we going to rebuild public health in Libya?. Journal of the Royal Society of Medicine, 2011, 104, 490-492.	1.1	8
193	How is chronic nonâ€communicable respiratory conditions research reported in European newspapers? An impact assessment for policy. Clinical Respiratory Journal, 2017, 11, 657-665.	0.6	8
194	Tobacco in post-conflict settings: the case of Iraq. Ecancermedicalscience, 2017, 11, 735.	0.6	8
195	Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapies. Annals of Oncology, 2018, 29, 773-774.	0.6	8
196	The value of European immigration for high-level UK research and clinical care: cross-sectional study. Journal of the Royal Society of Medicine, 2019, 112, 29-35.	1.1	8
197	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 2019, 114, 128-136.	1.3	8
198	Economics of Pediatric Cancer in Four Eastern Mediterranean Countries: A Comparative Assessment. JCO Global Oncology, 2020, 6, 1155-1170.	0.8	8

#	Article	IF	CITATIONS
199	One Piece of the Jigsaw for the Cancer Recovery Strategy: Prevalence of COVID-19 in Patients With Cancer. Cancer Control, 2020, 27, 107327482095084.	0.7	8
200	Evidence-based benchmarks for use of cancer surgery in high-income countries: a population-based analysis. Lancet Oncology, The, 2021, 22, 173-181.	5.1	8
201	Additional challenges faced by cancer patients in Gaza due to COVID-19. Ecancermedicalscience, 2020, 14, ed100.	0.6	8
202	Mammographic Screening in the Occupied Palestinian Territory: A Critical Analysis of Its Promotion, Claimed Benefits, and Safety in Palestinian Health Research. JCO Global Oncology, 2020, 6, 1772-1790.	0.8	8
203	Analysis of media reporting of The Lancet Oncology Commission. Lancet Oncology, The, 2012, 13, 12-13.	5.1	7
204	Shooting for the Moon or Flying Too Near the Sun? Crossing the Value Rubicon in Precision Cancer Care. Public Health Genomics, 2016, 19, 132-136.	0.6	7
205	The "Molecularly Unstratified―Patient: A Focus for Moral, Psycho-Social and Societal Research. Biomedicine Hub, 2017, 2, 1-8.	0.4	7
206	UK newspaper reporting of the NHS cancer drugs fund, 2010 to 2015: a retrospective media analysis. Journal of the Royal Society of Medicine, 2018, 111, 366-373.	1.1	7
207	The contribution of Cyprus to non-communicable diseases and biomedical research from 2002 to 2013: implications for evidence-based healthÂpolicy. Health Research Policy and Systems, 2018, 16, 82.	1.1	7
208	Gender Differences in Concerns About Participating in Cancer Research During the COVID-19 Pandemic. Cancer Control, 2021, 28, 107327482198931.	0.7	7
209	Lung cancer research and its citation on clinical practice guidelines. Lung Cancer, 2021, 154, 44-50.	0.9	7
210	Modelling palliative and end-of-life resource requirements during COVID-19: implications for quality care. BMJ Open, 2021, 11, e043795.	0.8	7
211	Surgical Services for Cancer Care. , 2015, , 223-238.		7
212	Impact of the COVID-19 Pandemic on Cancer Researchers in 2020: A Qualitative Study of Events to Inform Mitigation Strategies. Frontiers in Public Health, 2021, 9, 741223.	1.3	7
213	America's cancer care crisis—is Europe any better?. Lancet, The, 2013, 382, 1628.	6.3	6
214	The impacts of diabetes research from 31 European Countries in 2002 to 2013. Research Evaluation, 2018, 27, 270-282.	1.3	6
215	The â€~Good Friday Agreement' and cancer research on the island of Ireland: Evidence for the impact of a tripartite cancer research partnership. European Journal of Cancer, 2020, 129, 15-22.	1.3	6
216	The use of HUMINT in epidemics: a practical assessment. Intelligence and National Security, 2020, 35, 493-501.	0.3	6

#	Article	IF	CITATIONS
217	Research on lung cancer and its funding, 2004–2018. Ecancermedicalscience, 2020, 14, 1132.	0.6	6
218	A workforce survey of New Zealand medical oncologists. New Zealand Medical Journal, 2013, 126, 45-53.	0.5	6
219	COVID-19 and Cancer Global Modelling Consortium (CCGMC): A global reference to inform national recovery strategies. Journal of Cancer Policy, 2022, 32, 100328.	0.6	6
220	What really matters in cancer?. European Journal of Cancer, 2013, 49, 1669-1672.	1.3	5
221	Population Screening for Cancer in High-Income Settings: Lessons for Low- and Middle-Income Economies. Journal of Global Oncology, 2019, 5, 1-5.	0.5	5
222	Sanctions on Syria. The Lancet Global Health, 2020, 8, e1369.	2.9	5
223	Biomedicine and the soul of medicine: optimising the balance. Lancet Oncology, The, 2021, 22, 907-909.	5.1	5
224	Cancer research collaboration between the UK and the USA: reflections on the 2021 G20 Summit announcement. Lancet Oncology, The, 2022, 23, 460-462.	5.1	5
225	Clinical trial design in oncology. Lancet Oncology, The, 2004, 5, 759-763.	5.1	4
226	Cancer research in the UK: A policy review of the junior academic clinical faculty. Molecular Oncology, 2008, 1, 366-373.	2.1	4
227	Putting public health back into the global cancer agenda. Annals of Oncology, 2012, 23, 2995-2996.	0.6	4
228	Small and light arms violence reduction as a public health measure: the case of Libya. Conflict and Health, 2018, 12, 29.	1.0	4
229	Cancer control in low- and middle-income countries: time for action. Journal of the Royal Society of Medicine, 2019, 112, 213-217.	1.1	4
230	Weighing false hope in population anticancer drug decision making. Annals of Oncology, 2019, 30, 10-11.	0.6	4
231	Centralisation of Pancreatoduodenectomy in India: Where Do We Stand?. World Journal of Surgery, 2020, 44, 2367-2376.	0.8	4
232	"Choosing Wisely―for Cancer Care in India. Indian Journal of Surgical Oncology, 2020, 11, 4-6.	0.3	4
233	Mental health disorders research in Europe, 2001–2018. Evidence-Based Mental Health, 2020, 23, 15-20.	2.2	4
234	Veterinary intelligence: integrating zoonotic threats into global health security. Journal of the Royal Society of Medicine, 2021, , 014107682110353.	1.1	4

#	Article	IF	Citations
235	Cancer research in the 57 Organisation of Islamic Cooperation (OIC) countries, 2008–17. Ecancermedicalscience, 2020, 14, 1094.	0.6	4
236	New journal authorship criteria: how ecancermedicalscience is supporting authors and readers from underserved settings. Ecancermedicalscience, 2020, 15, ed106.	0.6	4
237	Mapping breast cancer journal publications in conflict settings in the MENA region: a scoping review. Ecancermedicalscience, 2020, 14, 1129.	0.6	4
238	Strategies for cancer prevention in Indiaâ€"Catching the â€"low hanging fruits'. Journal of Cancer Policy, 2014, 2, 105-106.	0.6	3
239	Achieving better cancer intelligence for global cancer control. Lancet, The, 2018, 391, 1003-1004.	6.3	3
240	Mapping the cancer patient information landscape: A comparative analysis of patient groups across Europe and North America. European Journal of Cancer, 2018, 92, 88-95.	1.3	3
241	The impact of Brexit on UK cancer research. Lancet Oncology, The, 2018, 19, 1276-1278.	5.1	3
242	Why we need an intelligence-led approach to pandemics: supporting science and public health during COVID-19 and beyond. Journal of the Royal Society of Medicine, 2021, 114, 12-14.	1.1	3
243	Changing Mortality and Place of Death in Response to Refugee Influx: A Population-Based Cross-Sectional Study in Jordan, 2005–2016. Journal of Palliative Medicine, 2021, 24, 1616-1625.	0.6	3
244	Policy Challenges for Cancer Research: A Call to Arms. Ecancermedicalscience, 2009, 1, 53.	0.6	3
245	The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: a systematic review of the early evidence Journal of Cancer Policy, 2022, , 100338.	0.6	3
246	The bioweapons convention's impact on bioindustry. Nature Biotechnology, 2000, 18, 806-806.	9.4	2
247	The Goldilocks' problem of cancer medicines. Lancet Oncology, The, 2010, 11, 1017-1018.	5.1	2
248	Developing cancer care institutions for the developing world – Investigator's response. Lancet Oncology, The, 2018, 19, 1436.	5.1	2
249	Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens. Lancet Oncology, The, 2019, 20, 1482-1485.	5.1	2
250	Cancer in the older Indian population: Understanding the current context in an emerging economy. Journal of Geriatric Oncology, 2022, 13, 273-281.	0.5	2
251	C-CRES: COVID-19 and cancer research engagement study Journal of Clinical Oncology, 2020, 38, 182-182.	0.8	2
252	Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. JCO Global Oncology, 2022, , .	0.8	2

#	Article	IF	CITATIONS
253	Cancer control in Chile – Authors' reply. Lancet Oncology, The, 2013, 14, e338.	5.1	1
254	Genes, genes, genes. Lancet Oncology, The, 2013, 14, e88.	5.1	1
255	Settlements and separation in the West Bank: future implications for health. Medicine, Conflict and Survival, 2014, 30, 4-10.	0.3	1
256	Screening mammography: Authors' response to Nyström and Tabar and colleagues. Journal of the Royal Society of Medicine, 2015, 108, 431-432.	1.1	1
257	Reply to the letter to the editor â€~Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al Annals of Oncology, 2016, 27, 2136-2137.	0.6	1
258	Do not use robotic surgery in oncology patients when conventional surgical approaches are equally effective $\hat{a}\in$ "Authors' reply. Lancet Oncology, The, 2019, 20, e241.	5.1	1
259	Medical Civil–Military Relationships: A Feasibility Study of a United Kingdom Deployment in South Sudan. Disaster Medicine and Public Health Preparedness, 2020, 14, 568-576.	0.7	1
260	USA stockpiling of remdesivir: How should the world respond?. Journal of Comparative Effectiveness Research, 2020, 9, 1243-1246.	0.6	1
261	The spin-off to civilian medical practice in the UK and USA from medical research developed during conflict. Scientometrics, 2021, 126, 1829-1839.	1.6	1
262	Targeting the value of targeted therapy. Oncotarget, 2017, 8, 90612-90613.	0.8	1
263	Methodology, results, and publication of oncology clinical trials: Insights from all the world's randomized controlled trials (RCTs) 2014-2017 Journal of Clinical Oncology, 2020, 38, 2019-2019.	0.8	1
264	Contingency planning for cancer care in low- and middle-income countries during the COVID-19 pandemic: a rapid assessment for future disaster resilience. Ecancermedicalscience, 2022, 16, 1339.	0.6	1
265	Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. Current Oncology, 2022, 29, 2530-2538.	0.9	1
266	<scp>Building Resilient Health Systems Intelligence: Adapting Indicators of Compromise for the Cyber-Bionexus /scp>. Health Security, 2021, 19, 625-632.</scp>	0.9	1
267	Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. Journal of Cancer Policy, 2022, , 100342.	0.6	1
268	Corrigendum to "Has the US Cancer Centre model been â€~successful'? Lessons for the European cancer community―[Mol. Oncol. 3 (2009) 192–203]. Molecular Oncology, 2009, 3, 483-483.	2.1	0
269	International Cancer Control Partnership. Lancet Oncology, The, 2014, 15, 385-386.	5.1	O
270	Clinically meaningful benefit: Half of the value equation. European Journal of Cancer, 2017, 83, 329-330.	1.3	0

#	Article	IF	CITATIONS
271	Adoption of robotic surgery: driven by market competition or a desire to improve patient care? – Authors' reply. Lancet Oncology, The, 2018, 19, e67.	5.1	O
272	Cancer control in member countries of Organization of Islamic Cooperation (OIC)â€"A status report & İstanbul declaration by the first ladies of OIC. Journal of Cancer Policy, 2018, 18, 25-32.	0.6	0
273	Support for UNRWA's survival. Lancet, The, 2018, 392, 1009-1010.	6.3	O
274	Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?. Seminars in Oncology, 2020, 47, 353-354.	0.8	0
275	Choosing Wisely for Cancer Care in India. Indian Journal of Surgery, 2020, 82, 6-8.	0.2	O
276	Abstract S12-03: Clinical and demographic characteristics associated with shorter time to COVID-19 death. , 2021, , .		0
277	Better to light a flamethrower, than curse the darkness. Journal of Cancer Policy, 2021, 27, 100271.	0.6	0
278	Mental health disorders research in the countries of the Organisation of Islamic Cooperation (OIC), 2008–17, and the disease burden: Bibliometric study. PLoS ONE, 2021, 16, e0250414.	1.1	0
279	Global perspectives on clinical cancer research: A comparison of randomized controlled trial (RCT) design and outcomes across high income and low-middle income countries Journal of Clinical Oncology, 2020, 38, 7021-7021.	0.8	0
280	"Choosing Wisely―for cancer care in India. Journal of Cancer Research and Therapeutics, 2020, 16, 955.	0.3	0
281	"Choosing Wisely―for Cancer Care in India. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 567-569.	0.1	0
282	Disparities in COVID-19 severity and risk of death in cancer patients: Experiences from a U.K. cancer center Journal of Clinical Oncology, 2020, 38, 285-285.	0.8	0